2,3-dinor-11β-PGF2α is a urinary metabolite of prostaglandin D2 (PGD2)—a lipid mediator produced from arachidonic acid via the cyclooxygenase (COX) pathway. Mast cells are a major source of PGD2. After PGD2 is released in tissues, it is rapidly converted into more stable downstream metabolites, including 11β-PGF2α and 2,3-dinor-11β-PGF2α, which are excreted in urine. Measuring these metabolites provides a noninvasive index of in-vivo PGD2 production and, by extension, mast-cell activation.
Also known as:
-
2,3-dinor-11β-PGF2α (urine)
-
Dinor-11β-PGF2α, U
-
PGD2 metabolite (urine)
-
u-PGD2-M (terminology varies by lab)
Why it matters
PGD2 is a potent bioactive mediator that can cause bronchoconstriction, vasodilation, increased vascular permeability, flushing, and nasal congestion. Elevated urinary PGD2 metabolites are therefore used as supportive evidence in conditions featuring mast-cell activation, such as:
-
Mast Cell Activation Syndrome (MCAS) and systemic mastocytosis
-
Aspirin-exacerbated respiratory disease (AERD) / NSAID-exacerbated respiratory disease
-
Allergic reactions and anaphylaxis (often transient spikes)
-
Chronic spontaneous urticaria, atopic asthma, allergic rhinitis
-
Some cutaneous mastocytosis flares and food/venom allergies during reactions
Important: This marker is supportive, not diagnostic on its own. It is typically interpreted alongside clinical symptoms and companion markers (e.g., serum tryptase, urinary N-methylhistamine, urinary leukotriene E4 [uLTE4]).
How the test is done
-
Specimen: Urine (often a spot sample normalized to creatinine; some centers may request a 24-hour collection).
-
Method: Usually LC-MS/MS for specificity and sensitivity.
-
Reporting units: Commonly pg/mg creatinine or ng/mmol creatinine (varies by laboratory).
-
Stability/handling: Keep cool; follow lab instructions carefully—improper handling can affect results.
Reference ranges
There is no universal cut-off. Reference intervals and decision thresholds vary by lab, assay, and whether the sample is a spot vs. 24-hour collection. Always compare your value with the lab’s own reference range on the report.
How to interpret results
Elevated u-2,3-dinor-11β-PGF2α (above lab reference)
Suggests increased PGD2 pathway activity, commonly due to mast-cell activation. Consider the clinical context:
-
Symptoms consistent with mast-cell mediator release (flushing, wheeze/bronchospasm, nasal congestion/rhinorrhea, abdominal cramping/diarrhea, hypotension during reactions).
-
Co-elevations in urinary N-methylhistamine, uLTE4, or a rise in serum tryptase during episodes (Δ tryptase ≥20% + 2 ng/mL over baseline supports mast-cell involvement).
-
Recent allergen exposure, anaphylaxis, or NSAID challenge in AERD can produce transient spikes.
Non-disease contributors / confounders (can raise or alter levels):
-
Medications:
-
COX inhibitors (NSAIDs, high-dose aspirin) generally suppress prostaglandin synthesis; however, in AERD, reactions to aspirin/NSAIDs are complex and can be accompanied by transient mediator surges during provocation.
-
Corticosteroids and mast-cell stabilizers (e.g., cromolyn) may lower levels over time.
-
-
Active infections, acute inflammation, or vigorous allergic exposure shortly before sampling.
-
Collection timing relative to symptom flares (levels can be episodic).
What to do next (clinically, with your clinician):
-
Correlate with symptom diary and consider paired sampling: one sample during/just after a flare and one baseline when asymptomatic.
-
Review companion markers (tryptase, uLTE4, N-methylhistamine).
-
Evaluate medication effects (NSAIDs, steroids, biologics like omalizumab, dupilumab; leukotriene modifiers).
-
If mast-cell disease is suspected, consider referral to allergy/immunology or hematology (for systemic mastocytosis evaluation when indicated).
Normal result
A normal value does not exclude mast-cell activation—mediator release can be intermittent and time-sensitive to flares. If suspicion remains high, clinicians often:
-
Repeat testing during symptoms,
-
Check other mediators, and
-
Assess tryptase dynamics (baseline vs. event-related rise).
Low result
Usually of limited standalone significance. Very low levels may reflect COX inhibition (e.g., steady NSAID use) or effective anti-inflammatory / anti-mast-cell therapy.
Clinical context & companion testing
Because no single mediator fits all patients or all timepoints, clinicians often combine:
-
Serum tryptase (baseline and during events),
-
Urinary leukotriene E4 (uLTE4) for cysteinyl-leukotriene pathway activity,
-
Urinary N-methylhistamine (histamine turnover),
-
Prostaglandin metabolites like 2,3-dinor-11β-PGF2α and 11β-PGF2α (PGD2 pathway).
This multi-analyte approach improves sensitivity for detecting mast-cell involvement.
Factors that can influence results
-
Timing: Collect as close to symptom onset as practical (often within 4–6 hours) for flare assessment.
-
Diet & supplements: Typically minimal effect, but always follow lab prep instructions.
-
Meds: NSAIDs/aspirin, COX-2 inhibitors, corticosteroids, mast-cell stabilizers, and certain biologics can shift levels (direction depends on drug and clinical context). Share a full med list with your clinician.
-
Renal function & hydration: Creatinine-normalized reporting helps, but extreme hydration or renal impairment can still affect interpretation.
How this marker is used in practice
-
Support diagnosis of mast-cell–mediated conditions in the right clinical setting.
-
Document objective mediator release in patients with unexplained flushing, anaphylactoid episodes, or bronchospasm.
-
Monitor response to therapy (e.g., after starting leukotriene modifiers, cromolyn, antihistamines, or biologics) when measured consistently with the same lab/method.
Practical testing tips
-
Ask whether your lab prefers a first-morning spot urine (with creatinine) or a 24-hour collection.
-
If evaluating flares, plan to collect during symptoms and consider a baseline sample on a stable day.
-
Verify units and reference range on your specific report; keep copies for comparison over time.
-
If you’re on medications that may affect prostaglandins, do not stop them without medical guidance—interpretation can account for them.
FAQs
Is this the same as 8-iso-PGF2α (F2-isoprostanes)?
No. F2-isoprostanes are markers of oxidative stress formed non-enzymatically. 2,3-dinor-11β-PGF2α reflects enzymatic PGD2 pathway activity, often tied to mast-cell activation.
Do I need both 11β-PGF2α and 2,3-dinor-11β-PGF2α?
Many labs measure one or both. Patterns can be informative, but either can serve as a surrogate for PGD2 production. Use the same lab and method for trend monitoring.
What’s a “good” level?
“Good/abnormal” depends on the lab-specific reference interval and your clinical picture. Elevated values are only actionable when correlated with symptoms and other markers.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.